175 related articles for article (PubMed ID: 24923562)
1. Circulating biomarkers in hepatocellular carcinoma.
Morris KL; Tugwood JD; Khoja L; Lancashire M; Sloane R; Burt D; Shenjere P; Zhou C; Hodgson C; Ohtomo T; Katoh A; Ishiguro T; Valle JW; Dive C
Cancer Chemother Pharmacol; 2014 Aug; 74(2):323-32. PubMed ID: 24923562
[TBL] [Abstract][Full Text] [Related]
2. A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.
Nam SJ; Yeo HY; Chang HJ; Kim BH; Hong EK; Park JW
Cancer Res Treat; 2016 Oct; 48(4):1229-1242. PubMed ID: 27034142
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study.
Hamaoka M; Kobayashi T; Tanaka Y; Mashima H; Ohdan H
PLoS One; 2019; 14(5):e0217586. PubMed ID: 31141571
[TBL] [Abstract][Full Text] [Related]
4. High-Specific Isolation and Instant Observation of Circulating Tumour Cell from HCC Patients via Glypican-3 Immunomagnetic Fluorescent Nanodevice.
Chu Q; Mu W; Lan C; Liu Y; Gao T; Guan L; Fang Y; Zhang Z; Liu Y; Liu Y; Zhang N
Int J Nanomedicine; 2021; 16():4161-4173. PubMed ID: 34168446
[TBL] [Abstract][Full Text] [Related]
5. Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry.
Mu H; Lin KX; Zhao H; Xing S; Li C; Liu F; Lu HZ; Zhang Z; Sun YL; Yan XY; Cai JQ; Zhao XH
World J Gastroenterol; 2014 May; 20(19):5826-38. PubMed ID: 24914343
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
[TBL] [Abstract][Full Text] [Related]
7. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
[TBL] [Abstract][Full Text] [Related]
8. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
Schulze K; Gasch C; Staufer K; Nashan B; Lohse AW; Pantel K; Riethdorf S; Wege H
Int J Cancer; 2013 Nov; 133(9):2165-71. PubMed ID: 23616258
[TBL] [Abstract][Full Text] [Related]
9. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.
Court CM; Hou S; Winograd P; Segel NH; Li QW; Zhu Y; Sadeghi S; Finn RS; Ganapathy E; Song M; French SW; Naini BV; Sho S; Kaldas FM; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
Liver Transpl; 2018 Jul; 24(7):946-960. PubMed ID: 29624843
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma.
Yi B; Wu T; Zhu N; Huang Y; Yang X; Yuan L; Wu Y; Liang X; Jiang X
J Nanobiotechnology; 2021 Mar; 19(1):74. PubMed ID: 33726759
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer.
Liu S; Wang M; Zheng C; Zhong Q; Shi Y; Han X
Clin Biochem; 2020 May; 79():54-60. PubMed ID: 32087138
[TBL] [Abstract][Full Text] [Related]
12. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.
Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D
J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma.
Ozkan H; Erdal H; Koçak E; Tutkak H; Karaeren Z; Yakut M; Köklü S
J Clin Lab Anal; 2011; 25(5):350-3. PubMed ID: 21919070
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.
Chen J; Cao SW; Cai Z; Zheng L; Wang Q
Cancer Biomark; 2017 Dec; 20(4):487-498. PubMed ID: 28869439
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two detection systems for circulating tumor cells among patients with renal cell carcinoma.
Bai M; Zou B; Wang Z; Li P; Wang H; Ou Y; Cui K; Bian J; Li S; Xu X
Int Urol Nephrol; 2018 Oct; 50(10):1801-1809. PubMed ID: 30120680
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
Hou JM; Greystoke A; Lancashire L; Cummings J; Ward T; Board R; Amir E; Hughes S; Krebs M; Hughes A; Ranson M; Lorigan P; Dive C; Blackhall FH
Am J Pathol; 2009 Aug; 175(2):808-16. PubMed ID: 19628770
[TBL] [Abstract][Full Text] [Related]
18. GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma.
Attallah AM; El-Far M; Omran MM; Abdelrazek MA; Attallah AA; Saeed AM; Farid K
Tumour Biol; 2016 Sep; 37(9):12571-12577. PubMed ID: 27380057
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
[TBL] [Abstract][Full Text] [Related]
20. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy.
Haruyama Y; Yorita K; Yamaguchi T; Kitajima S; Amano J; Ohtomo T; Ohno A; Kondo K; Kataoka H
Int J Cancer; 2015 Oct; 137(7):1643-51. PubMed ID: 25784484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
